刘群威,周胜华,海志杰

• 1:中南大学湘雅二医院心血管内科
• 2:北京民航总医院心内科

摘要(Abstract)：

目的观察在鼠颈总动脉血管损伤后血中CD40L、MMP-8水平和血管内膜增生情况以及他汀类药物干预后的影响。方法在鼠颈总动脉血管损伤模型上观察血管损伤及阿托伐他汀干预后的内膜增生情况,并应用ELISA方法检测血管损伤及阿托伐他汀干预后CD40L和MMP-8的血中浓度变化。结果与对照组比较,在鼠颈总动脉血管损伤后1周,血中CD40L和MMP-8浓度明显增高,分别为(0.97±0.11)ng/ml比(2.13±0.27)ng/ml,(9.12±1.39)ng/ml比(23.47±3.95)ng/ml,t值分别为2.13和23.47,P均<0.01。内膜明显增生(18.90±1.36)×103μm2比(69.13±4.38)×103μm2,F=16.145,P<0.01);2周时血中CD40L浓度降至(1.01±0.12)ng/ml,MMP-8浓度明显减弱为(12.16±1.45)ng/ml,而内膜增生更为明显(142.65±5.45)×103μm2。与手术损伤组比较,阿托伐他汀干预后血中CD40L和MMP-8浓度均明显下降,分别为(2.13±0.27)ng/ml比(1.37±0.19)ng/ml,(23.47±3.95)ng/ml比(14.48±2.08)ng/ml,t值分别为2.290和3.611,P均<0.05,内膜增生明显减轻(142.65±5.45)×103μm2比(81.76±4.35)×103μm2,F=12.737,P<0.05。结论鼠颈总动脉血管损伤后,内膜增生明显且CD40L和MMP-8血中浓度明显增高。血中CD40L和MMP-8浓度增高可能与平滑细胞迁移,新生内膜形成及血管重塑有关。阿托伐他汀可明显降低血中CD40L和MMP-8浓度,并减轻内膜增生。

关键词(KeyWords)： 阿托伐他汀;基质金属蛋白酶8;CD40配体

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘群威,周胜华,海志杰

参考文献(References)：

• [1]Libb P,Ridker PM,Maseri A.Inflammation and atherosclerosis.Circulation,2002,105:1135-1143.
• [2]Stary HC,Chandler AB,Glagov S,et al.A definition of initial,fatty stresk,and inter-mediate lession of atherosclerosis:a report from the committee on Vascular Lesion of Council on Atherosclerosis,American Heart Association.Circulation,1994,89:2462-2478.
• [3]Wenke K,Meiser B,Thiery J,et al.Simvastatin reduces graft vessel disease and mortality after heart transplantation-a four year randomized trial.Circulation,1997,96:1398-1402.
• [4]Ridker PM,Rifai N,Pfeffer MA,et al.Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events(CARE)Investigators.Circulation,1998,98:839-844.
• [5]Laman JD,de Smet BJ,Schoneveld A,et al.CD40-CD40L interactions in atherosclerosis.Immunol Today,1997,18:272-277.
• [6]Shimizu K,Schonbeck U,Mach F,et al.Host PPARalpha ligands are potent repressors of major histocompatibility CD40ligand deficiency induces long-term allograft survival and complex classⅡinduction in atheroma-associated Cells.Circ Res,2002,90:356-362.
• [7]Aukrust P,Muller F,Heland T,et al.Enhanced levels of soluble and membrane-bound CD40ligand in patients with unstable angina,possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.Circulation,1999,100:614-620.
• [8]Mach F,Schonbeck U,Sukhova GK,et al.Functional CD40ligand is expressed on human vascular endothelial Cells,smooth muscle Cells,and macrophages:Implication for CD40-CD40ligand in atherosclerosis.Proc Natl Acad Sci USA,1997,94:1931-1936.
• [9]Brooks PC,Strmblad S,Sanders LC,et al.Localization of matrix metalloproteinase MMP-2to the surface of invasive Cells by interaction with Integrin alpha beta3.Cell,1996,85:683-693.
• [10]Gabay C,Kushner I.Acutephase proteins and other systemic responses to inflammation.N Engl J Med,1999,340:448-454.
• [11]Herman MP,Sukhova GK,Libby P,et al.Expression of neutrophil collagenase(matrix metalloproteinase-8)in human atheroma:a novel collagenolytic pathway suggested by transcriptional profiling.Circulation,2001,104:1899-1904.
• [12]Ridker PM,Cashman M,Stampfer MJ,et al.Inflammation,aspirin and the risk of cardiovascular disease in apparently healthy men.N Engl J Med,1997,336:973-979.
• [13]Bendeck MP,Zempo N,Clowes AW,et al.Smooth muscle cell migration and matrix metalloproteinases expression after arterial injury in the rat.Circ Res,1994,75:539-545.
• [14]Bilato C,Curto KA,Monticone RE,et al.The inhibition of vascular smooth muscle Cell migration by peptide and antibody antagonists of the integrin complex is reversed by activated calcium/calmodulin-dependent protein kinaseⅡ.J ClinInvest,1997,100:693-704.